{"id":"NCT00311363","sponsor":"XenoPort, Inc.","briefTitle":"Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.","officialTitle":"A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2006-04-05","resultsPosted":"2011-05-25","lastUpdate":"2013-07-22"},"enrollment":327,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome"],"interventions":[{"type":"DRUG","name":"GEn (XP13512)","otherNames":["Gabapentin Enacabil","XP13512"]},{"type":"DRUG","name":"GEn (XP13512)","otherNames":["Gabapentin Enacarbil","XP13512"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"GEn (XP13512) 1200 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).","primaryOutcome":{"measure":"Percentage of Participants Who Experienced a Relapse During the Double-Blind Treatment Period","timeFrame":"DB Treatment Period; Days 169 to 252 (Weeks 24 to 36)","effectByArm":[{"arm":"DB Placebo","deltaMin":22.7,"sd":null},{"arm":"DB GEn 1200 mg","deltaMin":9.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0158"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20511481"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":326},"commonTop":["Somnolence","Dizziness","Headache","Nasopharyngitis","Nausea"]}}